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An Unusual Presentation of Renal Cell Carcinoma with Tumor Thrombus
Joon Soo Kim, Paul Gribben, Jennifer Fillaus
Mentor: Jennifer Fillaus
Program: Nephrology
Renal cell carcinoma (RCC) is the most 
common primary renal neoplasm. Here we 
present a patient with a 3 month onset of 
lower extremity swelling and worsening 
renal function found to be due to advanced 
RCC with extensive tumor burden and rapid 
subsequent decline.
A middle-aged patient was referred to 
nephrology clinic for proteinuria and an 
elevated creatinine from a baseline of 0.9 
to 1.5mg/dL over three months. The patient 
complained of bilateral leg swelling, shortness 
of breath, weakness, five-pound weight loss 
over the last 3 months. Vital signs were 
unremarkable. Physical examination was 
notable for 2+ bilateral ankle edema. CMP 
was unremarkable except for a creatinine 
of 1.5mg/dL and alkaline phosphatase of 
581U/L (100U/L three months ago). Urine 
protein/creatinine ratio was 4.29. Blood 
electrophoresis with immunofixation and 
free light chain ratio were all within normal 
range. The patient had normocytic anemia 
(Hgb 9.8mg/dL), iron saturation of 10%. 
Renal ultrasound revealed a thickened left 
renal cortex and poorly visualized left renal 
vein. Subsequent imaging revealed a 6cm 
left renal mass with tumor thrombus in the 
left renal vein with extension into the IVC 
from the iliac vein bifurcation to the right 
atrium. A lytic lesion was noted in the L2 
spine. A biopsy of the lytic lesion revealed 
metastatic clear cell RCC. The patient rapidly 
deteriorated from obstructive shock, acute 
renal failure, significant acidosis, congestive 
hepatopathy, and transudative ascites (with no 
tumor cells).
RCC should always be a part of the 
differential diagnosis when evaluating leg 
swelling, proteinuria, or elevated creatinine. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.071
Eculizumab for the Treatment of Recurrent C3 Glomerulonephritis Caused by C3 Gain of Function Mutation 
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Introduction: C3 glomerulonephritis (C3GN) 
is a glomerular disease caused by excessive 
activation of the alternative complement 
pathway and often leads to end-stage renal 
disease. Following kidney transplantation, 
the recurrence risk is high and may cause 
premature allograft failure. Eculizumab 
prevents the membrane attack complex 
(MAC) formation and provides terminal 
complement inhibition. Here we present a 
case of early recurrent post-transplant C3GN 
in a patient with a C3 gene mutation that was 
successfully treated with eculizumab.
Case Description: A middle-aged patient 
with a history of chronic kidney disease 
received a living unrelated kidney transplant. 
Prior to the transplant, the patient was 
diagnosed with C3GN which was refractory 
to corticosteroids, mycophenolate, and 
rituximab. Evaluation revealed a C3 gain of 
function mutation. Complement inhibitory 
factors were normal and the patient did not 
have a C3 nephritic factor. An elevated level 
of soluble MAC (sMAC) was noted prior to 
transplantation. The patient had immediate 
graft function following transplant and was 
maintained on tacrolimus, mycophenolate, 
and prednisone following basiliximab 
induction. The patient’s creatinine reached a 
nadir of 1.1 mg/dl, but he/she developed early 
acute allograft dysfunction and proteinuria 
within the first few weeks of transplant and 
biopsy revealed early recurrence of C3GN. 
The patient was treated with high dose 
corticosteroids and plasmapheresis, but 
continued progression of renal dysfunction 
with rising sMAC levels, proteinuria, and 
activity of C3GN on a repeat biopsy. After 
initiation of eculizumab, the sMAC levels 
normalized, proteinuria resolved, and the 
allograft function improved. The patient is 
now >1 year out from transplantation with 
stable allograft function and no evidence of 
complications related to the eculizumab.
Discussion: Eculizumab appears to have a 
role in select patients with recurrent C3GN. 
Since not all patients with C3GN improve 
with eculizumab, more research is needed to 
define patients expected to benefit from this 
therapy. Patients with recurrent C3GN due 
to a gain of function mutation in the C3 gene 
should be considered for early eculizumab 
therapy to preserve allograft function and 
decrease excessive complement activity. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.072
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Purpose: Radiation Therapy Oncology Group 
(RTOG) 9802 has established postoperative 
radiotherapy (RT) and chemotherapy 
sequentially as the new standard of care for 
patients with high-risk low grade glioma 
(LGG) meeting trial criteria. Although all 
patients in the trial received sequential 
chemoradiation therapy (sCRT) with RT 
followed by chemotherapy, it is unknown 
whether concurrent chemoradiation therapy 
(cCRT) may offer advantages over sCRT. 
Methods: The National Cancer Database 
(NCDB) was queried for newly-diagnosed 
World Health Organization (WHO) grade II 
59 
glioma. Patients with unknown surgery, RT, 
or chemotherapy status were excluded, along 
with patients <40 years old who underwent 
gross total resection to coincide with RTOG 
9802 exclusion criteria. Chi squared, Fisher’s 
exact or Wilcoxon rank-sum tests evaluated 
differences in characteristics between groups. 
Kaplan-Meier analysis was used to evaluate 
overall survival (OS) between groups 
(sCRT vs. cCRT). Cox proportional hazards 
modeling determined variables associated 
with OS.
Results: In total, 496 patients were analyzed 
(n=416 [83.9%] cCRT, n=80 [16.1%] sCRT). 
Sequencing or concurrency of therapy did 
not independently influence survival on 
univariable/multivariable analysis. Factors 
associated with worse overall survival (OS) 
on multivariable analysis included advanced 
age (p<0.001) while mixed glioma (p=0.017) 
and oligodendroglioma (p=0.005) were 
associated with better OS than astrocytoma 
histologies. 
Conclusions: This is the only known analysis 
of cCRT versus sCRT for LGG. There is no 
evidence that cCRT improves outcomes over 
sCRT. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.073
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